scholarly journals Amphotericin B Lipid Complex in the Management of Invasive Aspergillosis in Immunocompromised Patients

2005 ◽  
Vol 40 (Supplement_6) ◽  
pp. S392-S400 ◽  
Author(s):  
Pranatharthi H. Chandrasekar ◽  
James I. Ito
Keyword(s):  
Invasive Aspergillosis ◽  
Amphotericin B ◽  
Immunocompromised Patients ◽  
Lipid Complex ◽  
Amphotericin B Lipid Complex

Apparent lack of cross-reactivity for infusion-related reactions between two forms of lipid-based amphotericin B

2013 ◽  
Vol 70 (12) ◽  
pp. 1047-1051 ◽  
Author(s):  
Mitchell S. Buckley ◽  
Clint S. Anderson ◽  
Shardool A. Patel ◽  
Melanie J. Yerondopoulos ◽  
Laura M. Wicks ◽  
...  
Keyword(s):  
Invasive Aspergillosis ◽  
Amphotericin B ◽  
Adverse Reactions ◽  
Cross Reactivity ◽  
Alternative Formulation ◽  
Lipid Complex ◽  
Apparent Lack ◽  
Course Of Action ◽  
Amphotericin B Lipid Complex ◽  
Alternative Lipid

Abstract Purpose The case of a patient who experienced probable infusion-related reactions to amphotericin B lipid complex (ABLC) but tolerated continued amphotericin B therapy after a switch to an alternative lipid-based formulation is reported. Summary A 28-year-old immunocompromised man with pneumonia, respiratory failure, and neutropenic fever was initiated on ABLC and other antibiotics for suspected invasive aspergillosis. Due to the patient’s deteriorating renal function, the use of amphotericin B was deemed preferable to the standard therapy for invasive aspergillosis (voriconazole) even though he had experienced likely infusion-related reactions to ABLC on two prior occasions. During the infusion of ABLC, significant increases in the man’s temperature, respiratory rate, systolic blood pressure, and heart rate were observed. Although those symptoms were suspected to be infusion related, it was decided that continuing amphotericin B therapy with an alternative lipid-based form of the drug was the best course of action. After the patient was switched to liposomal amphotericin B one day later, no further infusion-related adverse reactions were noted for the duration of therapy. While this case suggests that adverse reactions to one type of amphotericin B might not occur with the use of an alternative formulation, further research is needed to better define the potential for cross-reactivity among various forms of amphotericin B and related safe-infusion practices. Conclusion A patient with invasive aspergillosis who experienced likely infusion- related reactions to ABLC was able to tolerate continued amphotericin B therapy after a switch to the liposomal formulation.

scholarly journals Invasive aspergillosis a complication severe respiratory viral infections (influenza and COVID-19)

2021 ◽  
Vol 13 (4) ◽  
pp. 14-24
Author(s):  
N. N. Klimko ◽  
O. V. Shadrivova
Keyword(s):  
Risk Factors ◽  
Invasive Aspergillosis ◽  
Amphotericin B ◽  
Viral Infections ◽  
Underlying Disease ◽  
Lipid Complex ◽  
Sabouraud Agar ◽  
Severe Influenza ◽  
Life Threatening ◽  
Amphotericin B Lipid Complex

Invasive aspergillosis is a life-threatening complication in patients with severe influenza and COVID-19 in intensive care units. Risk factors for the invasive aspergillosis development are transitory immunosuppression associated with severe influenza and COVID-19, as well as the use of glucocorticosteroids and immunosuppressive therapy. In the presence of risk factors, suspected clinical and radiological signs of invasive aspergillosis, bronchoscopy and examination of material from the lower respiratory tract are necessary: test for galactomannan, microscopy with white calcofluor staining and inoculation on Sabouraud agar medium. Voriconazole or are recommended as first-line treatment for invasive aspergillosis in patients with severe influenza and COVID-19. Amphotericin B Liposomal, Amphotericin B Lipid Complex, and Caspofungin are the alternative options for the invasive aspergillosis treatment. Combination therapy is possible. It is necessary to control the underlying disease with eliminate or reduce the severity of risk factors. 

Amphotericin B Lipid Complex in the Management of Invasive Fungal Infections in Immunocompromised Patients

2011 ◽  
Vol 31 (11) ◽  
pp. 745-758 ◽  
Author(s):  
Matteo Bassetti ◽  
Franco Aversa ◽  
Filippo Ballerini ◽  
Fabio Benedetti ◽  
Alessandro Busca ◽  
...  
Keyword(s):  
Amphotericin B ◽  
Fungal Infections ◽  
Invasive Fungal Infections ◽  
Immunocompromised Patients ◽  
Lipid Complex ◽  
Amphotericin B Lipid Complex
Sign in / Sign up

Export Citation Format

Share Document